Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ehj.2004.04.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of different tirofiban administration times in patients with no-reflow myocardial infarction during percutaneous coronary intervention.
Pak J Med Sci
October 2024
Huiping Yu, Department of Cardiovascular Medicine, Hanyang Hospital affiliated to Wuhan University of Science and Technology, Wuhan, Hubei Province 430050, P.R. China.
Objective: To compare the effectiveness of different tirofiban administration time windows in patients with no-reflow myocardial infarction (MI) during percutaneous coronary intervention (PCI).
Methods: This single centre retrospective observational study included patients with no-reflow MI, undergoing PCI at the Hanyang Hospital affiliated to Wuhan University of Science and Technology from March 2020 to May 2023. All patients were administered tirofiban.
Intracoronary microcatheter indwelling for continuous pumping of low-dose thrombolytic drugs: A new approach to reperfusion in acute myocardial infarction.
Medicine (Baltimore)
April 2024
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Reperfusion therapy of acute myocardial infarction (AMI) refers to physical or chemical recanalization and restoration of blood flow to an occluded coronary artery, and current techniques for reperfusion therapy include intravenous thrombolysis, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). The number of patients receiving emergency CABG in the real world is decreasing due to the disadvantages of CABG and the improvement in PCI procedures. Thrombolytic therapy has some disadvantages such as low recanalization rate, high risk of reocclusion and bleeding, and short time window.
View Article and Find Full Text PDFBackground No-reflow phenomenon (NRP) remains a challenge in ST-elevation myocardial infarction (STEMI) patients. We determined the efficacy and safety of early intracoronary administration of nicorandil as an adjunct to primary percutaneous coronary intervention (pPCI) in STEMI patients to reduce the risk of NRP. Materials and methods In this single-center case-control prospective study, 100 STEMI patients who underwent pPCI had thrombectomy performed using a suction catheter, and tirofiban (10 mg/kg) was injected distal to the vascular lesion.
View Article and Find Full Text PDFPhase 1/2a Trial of ISPASM.
Stroke
December 2021
Department of Neurosurgery (M.Z., A.P., E.R., D.H.), University of Iowa Hospital and Clinics.
Background And Purpose: Microthrombosis could play a role in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Tirofiban has shown promising results in reducing delayed cerebral ischemia in retrospective studies. However, the safety of using tirofiban in aneurysmal subarachnoid hemorrhage is not rigorously established.
View Article and Find Full Text PDFThree novel ATG16L1 mutations in a patient with acute myocardial infarction and coronary artery ectasia: A case report.
Medicine (Baltimore)
January 2021
Shandong Provincial Key Laboratory of Cardiac Disease Diagnosis and Treatment.
Introduction: Acute myocardial infarction (AMI) is a specific type of coronary artery disease (CAD) caused by the rupture of coronary atherosclerotic plaques. Coronary artery ectasia (CAE) is a rare phenotype of cardiovascular disease that may promote thrombosis and inflammatory responses leading to myocardial infarction due to abnormal dilatation of blood vessels and coronary blood flow disorders. It is a complicated disease and shows interaction between genetic and environmental factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!